| Date | Title | | | 11/05/09 | Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer| Phase 3 Results Reinforce Importance of KRAS Status
THOUSAND OAKS, Calif., Nov. 5 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that the Phase 3 PRIME "203" trial evaluating Vectibix® (panitumumab) administered in combination with FOLFOX (an oxaliplatin-based chemotherapy) as a first-line treatment of metastatic colorectal cancer (mCRC) failed to meet a secondary endpoint of overall survival. Earlier this year, it was announced that the trial met its primary endpoint b... |
|  | | 11/04/09 | Call for Applications: The Amgen Award for Science Teaching Excellence| 34 Outstanding Teachers Will Be Recognized in Communities Where Amgen Operates
THOUSAND OAKS, Calif., Nov. 4 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that it now invites applications for its 19th annual Amgen Award for Science Teaching Excellence (AASTE). This award is designed to recognize and honor extraordinary science teachers at the K-12 level who significantly impact their students through exemplary science teaching and who achieve demonstrated results in student le... |
| | | 10/30/09 | Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints| Aranesp(R) (Darbepoetin Alfa) Did Not Reduce the Risk of Mortality, Cardiovascular Morbidity, or End Stage Renal Disease
THOUSAND OAKS, Calif., Oct. 30 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced the publication of results from TREAT (the Trial to Reduce Cardiovascular Events with Aranesp® Therapy), a large, randomized, double-blind, placebo-controlled, Phase 3 pivotal study of patients with chronic kidney disease (CKD) not on dialysis, moderate anemia and type-2 di... |
| | | 10/21/09 | Amgen's Third Quarter 2009 Adjusted Earnings Per Share Increased 21 Percent to $1.49| Third Quarter 2009 Revenue Decreased 2 Percent to $3.8 Billion
THOUSAND OAKS, Calif., Oct. 21 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) reported adjusted earnings per share (EPS) of $1.49 for the third quarter of 2009, an increase of 21 percent compared to $1.23 for the third quarter of 2008. Adjusted net income increased 16 percent to $1,518 million in the third quarter of 2009 compared to $1,308 million in the third quarter of 2008.
Total revenue decreased 2... |
| |
|
